JP2021525738A - 複素環誘導体及びその使用 - Google Patents

複素環誘導体及びその使用 Download PDF

Info

Publication number
JP2021525738A
JP2021525738A JP2020566706A JP2020566706A JP2021525738A JP 2021525738 A JP2021525738 A JP 2021525738A JP 2020566706 A JP2020566706 A JP 2020566706A JP 2020566706 A JP2020566706 A JP 2020566706A JP 2021525738 A JP2021525738 A JP 2021525738A
Authority
JP
Japan
Prior art keywords
pyrazine
pyrido
bromo
mmol
imidazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020566706A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525738A5 (cg-RX-API-DMAC7.html
Inventor
コ・グァンソク
イ・スノク
クォン・ヨンジン
ユン・ジフン
チョ・ナムチョル
イ・ジウン
キム・ジョンスク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
C&C Research Laboratories
Original Assignee
C&C Research Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C&C Research Laboratories filed Critical C&C Research Laboratories
Publication of JP2021525738A publication Critical patent/JP2021525738A/ja
Publication of JP2021525738A5 publication Critical patent/JP2021525738A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2020566706A 2018-05-31 2019-05-31 複素環誘導体及びその使用 Withdrawn JP2021525738A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2018-0062254 2018-05-31
KR20180062254 2018-05-31
PCT/KR2019/006553 WO2019231270A1 (en) 2018-05-31 2019-05-31 Heterocyclic derivatives and use thereof

Publications (2)

Publication Number Publication Date
JP2021525738A true JP2021525738A (ja) 2021-09-27
JP2021525738A5 JP2021525738A5 (cg-RX-API-DMAC7.html) 2022-04-04

Family

ID=68698381

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020566706A Withdrawn JP2021525738A (ja) 2018-05-31 2019-05-31 複素環誘導体及びその使用

Country Status (12)

Country Link
US (1) US20210198259A1 (cg-RX-API-DMAC7.html)
EP (1) EP3807282A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021525738A (cg-RX-API-DMAC7.html)
KR (1) KR102344295B1 (cg-RX-API-DMAC7.html)
CN (1) CN112204032A (cg-RX-API-DMAC7.html)
AU (1) AU2019279421A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020023946A2 (cg-RX-API-DMAC7.html)
CA (1) CA3098825A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020011955A (cg-RX-API-DMAC7.html)
SG (1) SG11202010985TA (cg-RX-API-DMAC7.html)
TW (1) TW202021969A (cg-RX-API-DMAC7.html)
WO (1) WO2019231270A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
CN116057045B (zh) 2020-06-05 2026-06-09 金耐特生物制药公司 成纤维细胞生长因子受体激酶抑制剂
EP4067357A1 (en) * 2021-03-30 2022-10-05 JW Pharmaceutical Corporation Novel crystalline form of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine hydrogen sulfate monohydrate
CN113929634A (zh) * 2021-11-22 2022-01-14 山西永津集团有限公司 一种2,3-二溴喹喔啉的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE358395B (cg-RX-API-DMAC7.html) * 1967-09-27 1973-07-30 Siegfried Ag
EP1613629A1 (en) * 2003-03-27 2006-01-11 Pfizer Products Inc. Substituted 4-amino 1,2,4 triazolo 4,3-a quinoxalines
JP2012502067A (ja) * 2008-09-10 2012-01-26 カリプシス・インコーポレーテッド 疾患の治療のためのヒスタミン受容体の複素環阻害剤
TW201204727A (en) * 2010-03-10 2012-02-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
TW201206936A (en) * 2010-07-19 2012-02-16 Alcon Res Ltd Methods and compositions for the treatment of allergy
CN103889986B (zh) * 2011-09-30 2017-07-21 C&C新药研究所 新杂环衍生物及其应用
WO2014152029A2 (en) * 2013-03-15 2014-09-25 Epigenetix, Inc. Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
US10407423B2 (en) * 2015-11-16 2019-09-10 Fundación Para La Investigación Médica Aplicada Compounds as inhibitors of DNA methyltransferases
JP7212612B2 (ja) * 2016-07-28 2023-01-25 プロメガ コーポレイション セレンテラジン類縁体

Also Published As

Publication number Publication date
EP3807282A4 (en) 2022-03-02
US20210198259A1 (en) 2021-07-01
KR102344295B1 (ko) 2021-12-29
CA3098825A1 (en) 2019-12-05
SG11202010985TA (en) 2020-12-30
EP3807282A1 (en) 2021-04-21
TW202021969A (zh) 2020-06-16
KR20190137013A (ko) 2019-12-10
CN112204032A (zh) 2021-01-08
MX2020011955A (es) 2021-01-15
AU2019279421A1 (en) 2020-12-03
BR112020023946A2 (pt) 2021-02-23
WO2019231270A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
US12247027B2 (en) P2X7 modulators
JP6031107B2 (ja) 新規な複素環誘導体及びその用途
TW202241906A (zh) 吲唑化合物
JP2023538060A (ja) 二環化合物、それを含む組成物、及びそれらの使用
KR102344295B1 (ko) 헤테로사이클 유도체 및 이의 용도
JP2021525738A5 (cg-RX-API-DMAC7.html)
HK40034987A (en) Heterocyclic derivatives and use thereof
HK1246278A1 (en) P2x7 modulators
HK1218541B (en) P2x7 modulators

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220323

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20221226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221226